Abstract
The COVID-19 pandemic has initiated an unprecedented worldwide effort to characterize its evolution through the mapping of mutations of the coronavirus SARS-CoV-2. The early identification of mutations that could confer adaptive advantages to the virus, such as higher infectivity or immune evasion, is of paramount importance. However, the large number of currently available genomes precludes the efficient use of phylogeny-based methods. Here we present CoVtRec, a fast and scalable Topological Data Analysis approach for the surveillance of emerging adaptive mutations in large genomic datasets. Our method overcomes limitations of state-of-the-art phylogeny-based approaches by quantifying the potential adaptiveness of mutations merely by their topological footprint in the genome alignment, without resorting to the reconstruction of a single optimal phylogenetic tree. Analyzing millions of SARS-CoV-2 genomes from GISAID, we find a correlation between topological signals and adaptation to the human host. By leveraging the stratification by time in sequence data, our method enables the high-resolution longitudinal analysis of topological signals of adaptation. We characterize the convergent evolution of the coronavirus throughout the whole pandemic to date, report on emerging potentially adaptive mutations, and pinpoint mutations in Variants of Concern that are likely associated with positive selection. Our approach can improve the surveillance of mutations of concern and guide experimental studies.
Competing Interest Statement
Raul Rabadan is a founder of Genotwin, he is member of the Scientific Advisory Board of AimedBio and consults for Arquimea Research.
Funding Statement
The authors acknowledge the use of de.NBI Cloud and the support by the High Performance and Cloud Computing Group at the Zentrum für Datenverarbeitung of the University of Tübingen and the Federal Ministry of Education and Research (BMBF) through grant no 031 A535A. This research was supported by the DFG Collaborative Research Center SFB/TRR 109 "Discretization in Geometry and Dynamics". M.B. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC 2181/1 - 390900948 (the Heidelberg STRUCTURES Excellence Cluster). L.H. thanks the Evangelisches Studienwerk Villigst for their support. M.N. was supported by the Vector Stiftung ("Topological Genomics"). A.O. acknowledges funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -- 281869850 (RTG 2229). This research was funded by the Federal Ministry of Education and Research (BMBF) and the Baden-Württemberg Ministry of Science as part of the Excellence Strategy of the German Federal and State Governments (KIT Centers, "Topological Genomics"), and by the Vector Stiftung ("Topological Genomics").
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No specific IRB protocol as data can be found in public repositories (GISAID).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Major revisions; new analyses added.
Data availability
The SARS-CoV-2 genome data used in this work are available from the GISAID EpiCov Database [18, 36] at https://www.gisaid.org. To view the contributors of each individual sequence with details such as accession number, Virus name, Collection date, Originating Lab and Submitting Lab and the list of Authors, visit https://doi.org/10.55876/gis8.230731by. Experimental data on viral phenotypes by Starr et al. and Greaney et al. is available from [3, Table S2] and [4, Table S3]. Data on fitness effects of Spike gene amino acid changes by Bloom & Neher is available from [108]. Data on filtration rules for highly homoplasic sites, problematic sites and potential artifacts in SARS-CoV-2 sequence alignments by Turakhia et al. and De Maio et al. is available from [46, 47]. Data on COSMIC mutational signatures for Genome GRCh37 by COSMIC is available from [109].
